Drug resistant falciparum malaria: Clinical consequences and strategies for prevention

Drug Resistance Updates

Volumn 4, Issue 3, 2001, Pages 187-196

  Price, R N ^a   Nosten, F ^a,b,c  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b SHOKLO MALARIA RESEARCH UNIT   (Thailand)

^c MAHIDOL UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; AMODIAQUINE; ANTIMALARIAL AGENT; ARTEMETHER PLUS BENFLUMETOL; ARTEMISIN DERIVATIVE; ARTESUNATE; ATOVAQUONE PLUS PROGUANIL; BIGUANIDE; BIGUANIDE DERIVATIVE; CHLOROQUINE; CHLORPHENIRAMINE; CLINDAMYCIN; DAPSONE; FANSIDAR; FOLIC ACID ANTAGONIST; HALOFANTRINE; HISTAMINE H1 RECEPTOR ANTAGONIST; MEFLOQUINE; PENFLURIDOL; PRIMAQUINE; PROGUANIL; PYRIMETHAMINE; QUININE; QUINOLINE DERIVATIVE; SULFADOXINE; SULFONAMIDE; TETRACYCLINE; VERAPAMIL;

COMBINATION CHEMOTHERAPY; DRUG COST; DRUG INDUCED DISEASE; DRUG POTENTIATION; DRUG RESEARCH; EARLY DIAGNOSIS; ENDEMIC DISEASE; HEALTH CARE FINANCING; HUMAN; MALARIA FALCIPARUM; MULTIDRUG RESISTANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW;

EID: 0035180748     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1054/drup.2001.0195     Document Type: Review

References (61)

1. Antimalarial drug resistance: The pace quickens
2. Averting a malaria disaster
3. Assessment of the pharmacodynamic properties of antimalarial drugs in vivo
4. The efficacy of pyrimethamine-sulfadoxine (Fansidar) in the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children
5. Mefloquine pharmacokinetic-pharmacodynamic models: Implications for dosing and resistance
6. Changing patterns of clinical malaria since 1965 among a tea estate population located in the Kenyan highlands
7. Factors contributing to anaemia following uncomplicated falciparum malaria
8. Chloroquine in Africa: Critical assessment and recommendations for monitoring and evaluating chloroquine therapy efficacy in sub-Saharan Africa
9. Childhood mortality during and after hospitalization in western Kenya: Effect of malaria treatment regimens
10. Anaemia, blood transfusion practices, HIV and mortality among women of reproductive age in western Kenya
11. The cell biology of sexual development in plasmodium
12. Risk factors for gametocyte carriage in uncomplicated falciparum malaria
13. Effects of artemisinin derivatives on malaria transmissibility
14. The differing impact of chloroquine and pyrimethamine/sulfadoxine upon the infectivity of malaria species to the mosquito vector
15. Short report: Gametocytes, chloroquine pressure, and the relative parasite survival advantage of resistant strains of falciparum malaria in west Africa
16. Effects of artesunatemefloquine combination on incidence of Plasmodium falciparum malaria and mefloquine resistance in western Thailand: A prospective study
17. Isolated malaria outbreak in Somalia: Role of chloroquine-resistant Plasmodium falciparum demonstrated in Balcad epidemic
18. Epidemiology of the emergence and spread of drug-resistant falciparum malaria in South-East Asia and Australasia
19. Economic implications of resistance to antimalarial drugs
20. Making malaria-treatment policy in the face of drug resistance
21. Evidence that a point mutation in dihydrofolate reductase-thymidylate synthase confers resistance to pyrimethamine in falciparum malaria
22. Sequence variation of the hydroxymethyldihydropterin pyrophosphokinase: Dihydropteroate synthase gene in lines of the human malaria parasite, Plasmodium falciparum, with differing resistance to sulfadoxine
23. The efficacy of antifolate combinations in Africa: A predictive model based on pharmacodynamic and pharmacokinetic analyses
24. Several alleles of the multidrug-resistance gene are closely linked to chloroquine resistance in Plasmodium falciparum
25. Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance
26. A molecular marker for chloroquine-resistant falciparum malaria
27. Pgh1 modulates sensitivity and resistance to multiple antimalarials in Plasmodium falciparum
28. Increased sensitivity to the antimalarials mefloquine and artemisinin is conferred by mutations in the pfmdr1 gene of Plasmodium falciparum
29. The pfmdr1 gene is associated with a multidrug-resistant phenotype in Plasmodium falciparum from the western border of Thailand
30. Mutations in Plasmodium falciparum cytochrome b that are associated with atovaquone resistance are located at a putative drug-binding site
31. Multigenic drug resistance among inbred malaria parasites
32. Antimalarial drug resistance and combination chemotherapy
33. Preventing antimalarial drug resistance through combinations
34. Treatment of Plasmodium falciparum malaria with pyrimethamine-sulfadoxine: Selective pressure for resistance is a function of long elimination half-life
35. Mating Patterns of Plasmodium falciparum
36. Estimation of inbreeding coefficients from genotypic data on multiple alleles, and application to estimation of clonality in malaria parasites
37. Antibiotic resistance: Lessons for the future
38. Clinical features cannot predict a diagnosis of malaria or differentiate the infecting species in children living in an area of low transmission
39. Estimates of the infectious reservoir of Plasmodium falciparum malaria in The Gambia and in Tanzania
40. The evolution of multiple drug resistance in malaria parasites
41. Modelling a predictable disaster: The rise and spread of drug-resistant malaria
42. Transmission control and drug resistance in malaria: A crucial interaction
43. The effect of combinations of qinghaosu (artemisinin) with standard antimalarial drugs in the suppressive treatment of malaria in mice
44. The chemotherapy of rodent malaria. LVIII. Drug combinations to impede the selection of drug resistance. Part. 2: The new generation-artemisinin or artesunate with longacting blood schizontocides
45. Randomised trial of artesunate and mefloquine alone and in sequence for acute uncomplicated falciparum malaria
46. Treatment of multidrug-resistant Plasmodium falciparum malaria with 3-day artesunate-mefloquine combination
47. Efficacy of six doses of artemether-lumefantrine (benflumetol) in multidrug-resistant Plasmodium falciparum malaria
48. The effect of artemisinin combined with standard antimalarials against chloroquine-sensitive and chloroquine-resistant strains of Plasmodium falciparum in vitro
49. Randomized controlled trial of artesunate plus tetracycline versus standard treatment (quinine plus tetracycline) for uncomplicated Plasmodium falciparum malaria in Brazil
50. Randomized trial of mefloquine-doxycycline, and artesunate-doxycycline for treatment of acute uncomplicated falciparum malaria
51. Efficacy of artesunate plus pyrimethamine-sulphadoxine for uncomplicated malaria in Gambian children: A double-blind, randomised, controlled trial
52. The effect of artesunate combined with standard antimalarials against chloroquine-sensitive and chloroquine-resistant strains of Plasmodium falciparum in vitro
53. Chemotherapy for falciparum malaria: The armoury, the problems and the prospects
54. Comparative efficacy of chloroquine plus chlorpheniramine and pyrlmethamine/sulfadoxine in acute uncomplicated falciparum malaria in Nigerian children
55. Drug development output from 1975 to 1996: What proportion for tropical diseases?
56. Donor responsibilities in rolling back malaria. Editorial